Medgenics, Inc.'s Presents Expanded Results of Phase I/II Study of EPODURE Biopump for the Treatment of Anemia at the American Society of Nephrology’s Kidney Week 2011
11/15/2011 9:07:25 AM
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that positive data from a Phase I/II clinical trial of EPODURE to treat anemia in chronic kidney disease patients was highlighted in a poster presentation at the American Society of Nephrology’s Kidney Week 2011, held November 8-13 in Philadelphia. The poster, titled “Sustained Erythropoiesis 6-30 months by the EPODURE Biopump in Patients with Chronic Kidney Disease: Further Results of Phase I/II Proof of Concept Trial,” was presented November 11th by Dr. Allen Nissenson of the David Geffen School of Medicine at UCLA.
comments powered by